Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EGFR mutation

- PMLiVE

Allergy specialist Circassia buys asthma firms

British-based company acquires Sweden’s Aerocrine and privately held Prosonix

Roche Basel Switzerland

Roche moves closer to US filing for alectinib

Results showed alectinib able to shrink tumours in half of cases

- PMLiVE

EMA clears Novartis’ lung cancer drug Zykadia

First treatment option in Europe for patients with ALK-postitive NSCLC

- PMLiVE

Heart drug sales continue downward spiral

But revenue has stabilised after a tough three years of patent expiries

- PMLiVE

Payment to docs rules ‘an opportunity for pharma’

The industry’s reputation can be boosted by openness, say pharma compliance leaders

- PMLiVE

Merck files Keytruda for lung cancer

Filed to the FDA as a treatment option for NSCLC patients

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

AstraZeneca gains FDA orphan status for new cancer drug

Gains a longer patent life for the investigational lung disease drug

- PMLiVE

AstraZeneca and EHR firm to use drug alert system

Firm will team up with Practice Fusion to help keep patients on the right treatment pathway

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

Can Cinderella save us?

UK government warns over antibiotic resistant deaths

Cabinet Office document says the next 20 years is a crucial period for creating new medicines

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links